Monitoring levodopa levels in Parkinson's disease using a new sensor
Official title: Real-Time Levodopa Monitoring for Improved Management of Parkinson Disease
Run by University of California, San Diego · NCT04735627 · Data updated 2026-11-12
This study is testing a new sensor that can measure levodopa levels in real time for people with Parkinson's disease to help improve their treatment and manage symptoms better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 85 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | December 7, 2021 |
| Main results expected | December 2027 |
| Study ends | February 2028 |
| Registry record updated | February 11, 2025 |
| Trial ID | NCT04735627 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with clinically established Parkinson disease who are currently taking oral carbidopa/levodopa therapy.
✕Probably not a fit
Patients with other neurological conditions, major psychiatric diseases, or those who have undergone deep brain stimulation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project focuses on developing a minimally invasive sensor device, known as the Levodopameter, to monitor levodopa levels in real time for individuals with Parkinson disease. The study aims to assess the accuracy, tolerability, and safety of this device, which measures levodopa levels from body fluids such as capillary blood, sweat, and interstitial fluid. By providing continuous monitoring, the goal is to identify individualized treatment regimens that can improve disease management and reduce motor complications associated with fluctuating levodopa responses. This approach seeks to enhance the understanding of how levodopa affects patients on a day-to-day basis, potentially leading to better therapeutic outcomes.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective management of Parkinson disease symptoms through optimized levodopa dosing.
How similar studies have gone: While the concept of real-time monitoring of medication levels is innovative, similar approaches in other conditions have shown promise, suggesting potential for success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants must meet the Movement Disorders Society (MDS) diagnostic criteria for clinically established Parkinson disease. 2. Able to provide signed informed consent (in English or Spanish) 3. Mild, moderate, or severe Parkinson disease, able to ambulate (Hoehn and Yahr stages I-IV) 4. Taking instant release oral carbidopa/levodopa therapy 5. Either not taking, or on stable doses of any of the following antiparkinsonian medications: dopamine agonists, monoamine oxidase B (MAO-B) inhibitors or catecholamine O-methyl transferase (COMT) inhibitors Exclusion Criteria: 1. Other neurological conditions including but not limited to stroke, dementia (including Parkinson disease dementia), or traumatic brain injury 2. Co-existent major psychiatric disease 3. Uncontrolled, active medical conditions (e.g., heart, kidney, or liver failure, diabetes, etc.) 4. Status post deep brain stimulation (DBS) device placement 5. Any other condition, that in the opinion of the investigators, would place the participant at risk.
Where it's running
-
University of California San DIego
San Diego, California, United States Recruiting
Study contacts
- Principal investigator: Irene Litvan, MD — UCSD
- Study coordinator: Michael Skipworth
- Email: mskipworth@health.ucsd.edu
- Phone: 858-246-2537
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.